Key result
Co-expression network analysis and clinical validation identified AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, and MGAM as potential diagnostic biomarkers for acute myocardial infarction.
Why the study?
Specific diagnostic biomarkers have not been fully established and candidate regulatory targets for AMI remain to be determined.
Case-Control (n=109)
No
The hub genes AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, and MGAM were identified as potential novel biomarkers for the diagnosis of acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
These gene changes were associated with AMI; hypothesis-generating for diagnostic biomarkers, needing prospective validation before use.
Acute myocardial infarction (AMI) is a common cause of death in numerous countries. Understanding the molecular mechanisms of the disease and analyzing potential biomarkers of AMI is crucial. However, specific diagnostic biomarkers have thus far not been fully established and candidate regulatory targets for AMI remain to be determined. In the present study, the AMI gene chip dataset GSE48060 comprising blood samples from control subjects with normal cardiac function (n=21) and patients with AMI (n=26) was downloaded from Gene Expression Omnibus. The differentially expressed genes (DEGs) between the AMI and control groups were identified with the online tool GEO2R. The co-expression network of DEGs was analyzed by calculating the Pearson correlation coefficient of all gene pairs, mutual rank screening and cutoff threshold screening. Subsequently, the Gene Ontology (GO) database was used to analyze the genes' functions and pathway enrichment of genes in the most important modules was performed. Kyoto Encyclopedia of Genes and Genomes (KEGG) Disease and BioCyc were used to analyze the hub genes in the module to determine important sub-pathways. In addition, the expression of hub genes was confirmed by reverse transcription-quantitative PCR in AMI and control specimens. In the present study, 52 DEGs, including 26 upregulated and 26 downregulated genes, were identified. As key hub genes, three upregulated genes (AKR1C3, RPS24 and P2RY12) and three downregulated genes (ACSL1, B3GNT5 and MGAM) were identified from the co-expression network. Furthermore, GO enrichment analysis of all AMI co-expression network genes revealed functional enrichment mainly in 'RAGE receptor binding' and 'negative regulation of T cell cytokine production'. In addition, KEGG Disease and BioCyc analysis indicated functional enrichment of the genes RPS24 and P2RY12 in 'cardiovascular diseases', of AKR1C3 in 'cardenolide biosynthesis', of MGAM in 'glycogenolysis', of B3GNT5 in 'glycosphingolipid biosynthesis' and of ACSL1 in 'icosapentaenoate biosynthesis II'. In conclusion, the hub genes AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5 and MGAM are potential markers of AMI, and have potential application value in the diagnosis of AMI.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2021) conducted a case-control in Acute myocardial infarction (n=109). Acute myocardial infarction vs. Healthy controls was evaluated on Differential expression of hub genes (AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, MGAM) (p=<0.01). Co-expression network analysis and clinical validation identified AKR1C3, RPS24, P2RY12, ACSL1, B3GNT5, and MGAM as potential diagnostic biomarkers for acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: